Ruth He, MD, PhD
@RuthHe12
Followers
1K
Following
2K
Media
52
Statuses
539
@Columbiacancer medical oncologist specialized in gastrointestinal cancer and research on liver cancer and biliary cancer. All opinions are mine.
Joined September 2019
Looking forward to our GI Oncology Summit this Friday @HMethodistMD @MethodistHosp. Regional, National and International Esteemed faculty will be discussing 🔥 topics in GI malignancy. @ASCO @curecc @myESMO @VuMediHemOnc @DAVAOnc @OncLive
0
9
21
@NoureddinMD chairing the the first session in our Summit....lead the discussion on 🔥 topics of hematology...AI and others!
0
4
12
I am thrilled to congratulate our CMO, Dr. Juan W. Valle, for being named a 2025 Clarivate Highly Cited Researcher—one of the top 1% of researchers worldwide! His work continues to advance clinical research and care for the CCA community. 💚 https://t.co/AWzukMSPyw
manchester.ac.uk
Ten academics from The University of Manchester have been recognised among the world’s most influential, according to the Highly Cited Researchers rankings released by Clarivate.Highly Cited Resear...
0
3
17
@MaenAbdelrahim kicking off a great GI Oncology Summit @houstonmethodist. Thank you for the invitation to speak! @mayscancer @UTHealthSA
1
5
9
I am thrilled to celebrate Dr. Renuka Iyer’s appointment as CMO of @NCCN. She’s been an incredible partner to the CCA community through her work with CCF and her 2021 Mark R. Clements Award. We’re grateful for all she’s done and excited for what’s ahead. https://t.co/8475G74iTH
newswise.com
The National Comprehensive Cancer Network (NCCN)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care— announces...
0
3
5
Congratulations to Dr. Iyer on becoming the new CMO of the @NCCN! Having learned so much under her guidance, I’m beyond grateful for her mentorship, kindness, and example of what true leadership looks like. A real #BossLady changing the future of cancer care. @WomenInOncology
0
7
29
LEVIATHAN publication Get expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for #HCC 📺 from Prof. David Pinato (@DJPinato) 🤝 Programme endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets View/download the infographic:
0
5
7
⭐️We just spoke with @RuthHe12 who presented on transplant oncology for #cholangiocarcinoma and genomic-guided strategies @HMethodistMD. 🧬She provided valuable insight into the future of genomic-guided transplant oncology. Courtesy of Houston Methodist Hospital
0
4
8
Anwaar, congratulations! Great job!
A dream realized! 🎉 I presented the STELLAR-303 Phase 3 results today at #ESMO2025 — simultaneously published in The Lancet! Trial met its OS primary endpoint in MSS CRC. From CAMILLA to now, 8 years of relentless work. Full circle. A new era begins. Grateful. 🙏✨@OncoAlert
1
1
6
Learn more about @LombardiCancer's @RideBellRinger event on October 24th and 25th. Join or support the Ruesch Riders team today! https://t.co/Kp0joI08ub
0
2
5
⭐ In this roundtable discussion led by @RuthHe12, #GIOncology experts, like @MarkYarchoan, discuss the state of #HCC treatment, including the challenges in establishing effective perioperative strategies following the failure of #adjuvant atezo/bev: https://t.co/Bvd50MgFfq
0
2
3
What role do IO and IO combinations play in the systemic treatment landscape for pts w/ unresectable HCC? What do the latest trial data say about combining IO with locoregional therapies? Get an expert overview of the expanding role of IO for HCC Med Ed video from Prof.
0
2
29
In vivo CRISPR screens identify modifiers of CAR-T cell function in myeloma - targeting cell cycle inhibitor CDKN1B, or p27 might enhance CAR-T effectiveness. https://t.co/QstZTHYkyz
@MangusoLab @MarcelaMaus
@MassGeneralNews
0
4
22
October is #LiverCancerAwareness Month! At ILCA, we’re sharing the facts, the stories, and the fight against liver cancer. 💬 What’s one thing you wish more people knew about liver cancer? Share your thoughts, stories, or experiences and let’s raise awareness together.
1
5
10
This week, we highlighted research by Narayanan Sadagopan, Hongkun Wang, @ChYin89, @benweinbergmd, @mnoel3232, @ReetuMukherjiMD Xue Geng, @marshalj23, Branden S Moriarity, and @RuthHe12 published in @Nature_NPJ- https://t.co/jxf7mBFjkA. Full search: https://t.co/jcVbXq8iec.
0
2
3
.@benweinbergmd, discussed early results from the phase 2 EXPEL PANC trial (NCT05558982), evaluating BXCL701 plus pembrolizumab (Keytruda) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) after progression on chemotherapy. https://t.co/KNjrBiIpTQ via @onclive
0
3
5
From palliative care a decade ago to first-line curative intent treatment today, #Y90 radiation segmentectomy has been a welcome advancement in #livercancer treatment. 🧩 https://t.co/ayHAgb1hab
@RSNA @SIRspecialists @cirsesociety @APASLnews @JSHLiver @myESMO @BCLC_group
4
21
82
Fresh off the press! @benweinbergmd @ReetuMukherjiMD @mnoel3232 @marshalj23 @RuthHe12 , Thanks for your contribution to this project. Special thanks to Dr.Narayanan Sadagopan, our graduating fellow. https://t.co/LJMc8fpTvy.
0
4
15
Incredible news! #LR5 (Definite #HCC) criteria of #LIRADS, including #CEUS, are now fully aligned with #OPTN
#liver #transplant @UNOSNews @RadiologyACR @chemshift1
https://t.co/pRGEYa20oi
0
5
23